We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Vishal Yadav, CEO and founder, FDI India lists the reasons why he believes the Indian pharma sector is a “hot-bed” for investments, reflected as increasing FDI inflows, in an interaction with Viveka Roychowdhury.
In October 2020, the healthcare industry reported 86 deals worth $25.5 billion as compared to the last 12-month average (October 2019 to September 2020) of 78 deals worth $13 billion.
A report by the UK Bio Industry Association (BIA) and Informa Pharmaceutical Intelligence recorded that the UK biotech sector raised £2.2bn from investors in 2018.....